We are Pyridoxine CAS:65-23-6 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
CAS No: 65-23-6
Product Name: Pyridoxine
Density: 1.4±0.1 g/cm3
Boiling Point: 491.9±40.0 °C at 760 mmHg
Melting Point: 159-162ºC
Molecular Formula: C8H11NO3
Molecular Weight: 169.178
Flash Point: 251.3±27.3 °C
Exact Mass: 169.073898
Vapour Pressure: 0.0±1.3 mmHg at 25°C
Index of Refraction: 1.621
Storage condition: 2-8°C
Stability: Stable. Incompatible with strong oxidizing agents.
Water Solubility: H2O: 0.1 g/mL at 20 °C, clear, colorless
Appearance: White to practically white crystals or crystalline powder
Loss on Drying: ≤0.5%
Residue on Ignition: ≤0.1%
Heavy metals: ≤0.003%
Residual solvent: ≤0.5%
Lead: <2.0 ppm
Cadmium: <1.0 ppm
Arsenic: <1.0 ppm
Mercury: <0.1 ppm
Total Plate Count: ≤100cfu/g
Yeast and Mold: ≤10 cfu/g
It is mainly used to prevent rough skin, acne, sunburn, and itching. It is also suitable for the prevention and treatment of seborrheic alopecia, skin inflammation, general acne, seborrheic eczema and dandruff skin. Can be made into creams, lotions and alcohol solutions.
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Related News: Pharmaceutical intermediates and APIs belong to the fine chemical industry.Ácido 2,3-difluorofenilborónico CAS:121219-16-7 However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.3-Fluoro-2-Nitropyridine CAS:54231-35-5 However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.1-(4'-Sulfophenyl)-3-carboxy-5-pyrazolone In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.